Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIST-CKD
2025-525068-13-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Survodutide with Placebo (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2025-525068-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525068-13-00.